$43.29
2.24%
NYSE, Jan 02, 10:10 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US26622P1075
Symbol
DOCS

Doximity Stock price

$43.29
-7.27 14.38% 1M
-16.02 27.01% 6M
-0.99 2.24% YTD
-10.27 19.17% 1Y
+9.73 28.99% 3Y
-9.71 18.32% 5Y
-9.71 18.32% 10Y
-9.71 18.32% 20Y
NYSE, Closing price Fri, Jan 02 2026
-0.99 2.24%
ISIN
US26622P1075
Symbol
DOCS

New AI Insights on Doximity Insights AI Insights on Doximity

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$8.2b
Enterprise Value
$7.3b
Net debt
positive
Cash
$878.4m
Shares outstanding
188.1m
Valuation (TTM | estimate)
P/E
34.6 | 26.9
P/S
13.1 | 12.4
EV/Sales
11.7 | 11.0
EV/FCF
23.3
P/B
7.4
Financial Health
Equity Ratio
85.6%
Return on Equity
20.6%
ROCE
22.1%
ROIC
85.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$621.3m | $658.2m
EBITDA
$258.6m | $362.5m
EBIT
$246.8m | $355.9m
Net Income
$253.0m | $302.9m
Free Cash Flow
$312.1m
Growth (TTM | estimate)
Revenue
20.2% | 15.4%
EBITDA
21.9% | 50.6%
EBIT
22.2% | 54.7%
Net Income
45.3% | 35.7%
Free Cash Flow
43.6%
Margin (TTM | estimate)
Gross
90.2%
EBITDA
41.6% | 55.1%
EBIT
39.7%
Net
40.7% | 46.0%
Free Cash Flow
50.2%
More
EPS
$1.3
FCF per Share
$1.7
Short interest
6.0%
Employees
830
Rev per Employee
$690.0k
Show more

Is Doximity a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Doximity Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Doximity forecast:

16x Buy
59%
9x Hold
33%
2x Sell
7%

Analyst Opinions

27 Analysts have issued a Doximity forecast:

Buy
59%
Hold
33%
Sell
7%

Financial data from Doximity

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
621 621
20% 20%
100%
- Direct Costs 61 61
17% 17%
10%
560 560
21% 21%
90%
- Selling and Administrative Expenses 209 209
19% 19%
34%
- Research and Development Expense 104 104
21% 21%
17%
259 259
22% 22%
42%
- Depreciation and Amortization 12 12
15% 15%
2%
EBIT (Operating Income) EBIT 247 247
22% 22%
40%
Net Profit 253 253
45% 45%
41%

In millions USD.

Don't miss a Thing! We will send you all news about Doximity directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Doximity Stock News

Neutral
PRNewsWire
11 days ago
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
Positive
MarketBeat
17 days ago
At the start of the new year, investors seeking a fresh approach might consider stocks that are positioned for a reset. Companies trading at or near their lowest level for 2025 could be primed for gains in the new year if conditions are right.
Positive
Seeking Alpha
28 days ago
Doximity's Q2 results show record engagement and accelerating adoption of AI workflow tools, signaling deeper physician reliance on the platform. Revenue quality is improving as pharma clients shift from one-off ad buys to longer-term integrated programs. Doximity has a strong Rule-of-50 profile with high margins and $890m cash but no debt.
More Doximity News

Company Profile

Doximity, Inc. operates an online platform for medical professionals. It's cloud-based software has the ability to enable the users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. The company was founded by Konstantin Guericke, Nate Gross and Jeffrey A. Tangney in April 16, 2010 and is headquartered in San Francisco, CA.

Head office United States
CEO Jeffrey Tangney
Employees 830
Founded 2010
Website www.doximity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today